296 related articles for article (PubMed ID: 34985607)
1. Preferences for HIV Preexposure Prophylaxis Products Among Black Women in the U.S.
Irie WC; Calabrese SK; Patel RR; Mayer KH; Geng EH; Marcus JL
AIDS Behav; 2022 Jul; 26(7):2212-2223. PubMed ID: 34985607
[TBL] [Abstract][Full Text] [Related]
2. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia.
Paudel K; Gupta S; Gautam K; Wickersham JA; Khati A; Azwa I; Ha T; Shrestha R
J Community Health; 2023 Jun; 48(3):513-521. PubMed ID: 36732459
[TBL] [Abstract][Full Text] [Related]
3. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.
Schoenberg P; Edwards OW; Merrill L; Martinez CA; Stephenson R; Sullivan PS; Jones J
J Int AIDS Soc; 2023 Mar; 26(3):e26077. PubMed ID: 36951057
[TBL] [Abstract][Full Text] [Related]
4. Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old.
John SA; Zapata JP; Dang M; Pleuhs B; O'Neil A; Hirshfield S; Walsh JL; Petroll AE; Quinn KG
Sci Rep; 2023 Mar; 13(1):5116. PubMed ID: 36991027
[TBL] [Abstract][Full Text] [Related]
5. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
[TBL] [Abstract][Full Text] [Related]
6. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa.
Ogunbajo A; Tsai AC; Kanki PJ; Mayer KH
AIDS Behav; 2022 Jul; 26(7):2363-2375. PubMed ID: 35061117
[TBL] [Abstract][Full Text] [Related]
7. Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.
Parsons JT; Rendina HJ; Whitfield TH; Grov C
AIDS Behav; 2016 Jul; 20(7):1390-9. PubMed ID: 27000145
[TBL] [Abstract][Full Text] [Related]
8. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities.
Mansergh G; Kota KK; Stephenson R; Hirshfield S; Sullivan P
J Int AIDS Soc; 2021 Jan; 24(1):e25664. PubMed ID: 33481359
[TBL] [Abstract][Full Text] [Related]
9. Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons.
Okafor CN; Eaton L; Watson R
AIDS Behav; 2024 Jun; 28(6):2166-2174. PubMed ID: 38526639
[TBL] [Abstract][Full Text] [Related]
10. Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis.
Levy ME; Patrick R; Gamble J; Rawls A; Opoku J; Magnus M; Kharfen M; Greenberg AE; Kuo I
PLoS One; 2017; 12(8):e0183521. PubMed ID: 28827821
[TBL] [Abstract][Full Text] [Related]
11. Perceived Barriers to and Facilitators of Long-Acting Injectable HIV PrEP Use Among Black, Hispanic/Latino, and White Gay, Bisexual, and Other Men Who Have Sex With Men.
Tran NK; Martinez O; Scheim AI; Goldstein ND; Welles SL
AIDS Educ Prev; 2022 Oct; 34(5):365-378. PubMed ID: 36181495
[TBL] [Abstract][Full Text] [Related]
12. Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
John SA; Whitfield THF; Rendina HJ; Parsons JT; Grov C
AIDS Behav; 2018 Apr; 22(4):1184-1189. PubMed ID: 28913659
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men.
Dean LT; Predmore Z; Skinner A; Napoleon S; Chan PA; Raifman J
AIDS Behav; 2023 Aug; 27(8):2606-2616. PubMed ID: 36670210
[TBL] [Abstract][Full Text] [Related]
14. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
Meyers K; Rodriguez K; Moeller RW; Gratch I; Markowitz M; Halkitis PN
PLoS One; 2014; 9(12):e114700. PubMed ID: 25502768
[TBL] [Abstract][Full Text] [Related]
15. Social and structural factors associated with interest in HIV preexposure prophylaxis among Black women in the United States.
Irie WC; Calabrese SK; Mayer KH; Geng EH; Blackstock O; Marcus JL
AIDS Care; 2024 May; 36(5):672-681. PubMed ID: 38176016
[TBL] [Abstract][Full Text] [Related]
16. The Perceived Added Value of Bimonthly Injectable Pre-Exposure Prophylaxis According to West African Men Who Have Sex with Men: A Focus Group Study.
Reyniers T; Fiorentino M; Babo SAY; Ouedraogo M; Kanta I; Agbegnigan LE; Rojas D; Anoma C; Dah TTE; Mensah E; Keita BD; Spire B; Vuylsteke B; Laurent C
AIDS Patient Care STDS; 2023 Oct; 37(10):480-488. PubMed ID: 37862074
[TBL] [Abstract][Full Text] [Related]
17. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs.
Biello KB; Edeza A; Salhaney P; Biancarelli DL; Mimiaga MJ; Drainoni ML; Childs ES; Bazzi AR
AIDS Care; 2019 Oct; 31(10):1214-1220. PubMed ID: 30822103
[TBL] [Abstract][Full Text] [Related]
18. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
[TBL] [Abstract][Full Text] [Related]
19. Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China.
Meyers K; Wu Y; Qian H; Sandfort T; Huang X; Xu J; Zhang J; Xia W; Glidden D; Wu H; Shang H
AIDS Behav; 2018 Apr; 22(4):1217-1227. PubMed ID: 28707025
[TBL] [Abstract][Full Text] [Related]
20. Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment.
Cole SW; Glick JL; Campoamor NB; Sanchez TH; Sarkar S; Vannappagari V; Rinehart A; Rawlings K; Sullivan PS; Bridges JFP
BMJ Open; 2024 Apr; 14(4):e083837. PubMed ID: 38653510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
